# MCRB catalysts: Seres Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mcrb/catalysts

> Seres Therapeutics, Inc. (MCRB) has no upcoming catalysts in this calendar. The latest recorded is the Seres Therapeutics, Inc. earnings report, November 4, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Seres Therapeutics, Inc. |
| Ticker | MCRB (Nasdaq) |
| SEC CIK | 1609809 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mcrb |

## Cash runway

Cash $17.5M as of 2026-09-30; quarterly burn $10.5M; about 5.0 months of runway at that rate (XBRL company facts, accession 0001193125-26-446427).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2023 | [SER-155 FDA approval](https://sec-api.dev/pdufa/ser-155) | MCRB |  | completed, approved | "Validated therapeutic modality and platform: Seres pioneered the development and FDA approval of VOWST as the first-ever oral live microbiome therapeutic DRAMATIC CLINICAL BENEFIT - Preventing infection recurrence Approximately 88% FDA approved (April 2023) to prevent the recurrence of sustained clinical response rate (C. diff. recurrence, at up to 8 weeks) C. difficile infection in adults VOWST asset sale (completed September 2024) provided capital to support pipeline advancement and resulted in a more streamlined, focused organization Source:" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312525053473/d914751dex992.htm)) |
| November 7, 2024 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312524256654/d912869dex991.htm)) |
| March 13, 2025 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "CAMBRIDGE, Mass.March 13, 2025  Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported fourth quarter and full year 2024 financial results and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312525053473/d914751dex991.htm)) |
| May 7, 2025 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312525114430/d915177dex991.htm)) |
| August 6, 2025 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312525173985/d930624dex991.htm)) |
| November 5, 2025 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312525265708/d27174dex991.htm)) |
| March 12, 2026 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "CAMBRIDGE, Mass.- March 12, 2026 - Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported fourth quarter and full year 2025 financial results and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103034/d98522dex991.htm)) |
| Q2 2026 | [SER-155 topline data readout](https://sec-api.dev/pdufa/ser-155) | MCRB |  | scheduled | "Profile: SER-155 Status: Phase 1b Investigator sponsored trial, with readout expected Q2 2026 SER-155 irEC: Treat immune-related enterocolitis resulting from ICI therapies" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103034/d98522dex992.htm)) |
| May 5, 2026 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312526205009/d155025dex991.htm)) |
| August 5, 2026 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312526333820/d124829dex991.htm)) |
| November 4, 2026 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND ANNOUNCES PLANS FOR ADVANCING" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312526446185/d166389dex991.htm)) |

## Drugs

- [SER-109](https://sec-api.dev/pdufa/ser-109): 
- [SER-155](https://sec-api.dev/pdufa/ser-155): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mcrb/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MCRB catalysts: Seres Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mcrb/catalysts

```bibtex
@misc{secapidev_companies_mcrb_catalysts_20261116,
  title        = {MCRB catalysts: Seres Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mcrb/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mcrb_catalysts_20261116","title":"MCRB catalysts: Seres Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mcrb/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
